Skip to the content
  • 719-347-5400
  • info@realmofcaring.org
  • 719-347-5400
  • info@realmofcaring.org
  • Research
    • Observational Research Registry
    • Company Interest
    • Research Library
    • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Observational Research Registry
      • Printable Resources
      • Supported Brands
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Find a Provider
      • Locate a Healthcare Professional
      • MMJ Recommendations
  • Blog
    • Blog: Client Stories
    • Blog: Education
  • About
    • Who We Are
    • In the News
    • Supported Brands
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
Menu
  • Research
    • Observational Research Registry
    • Company Interest
    • Research Library
    • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Observational Research Registry
      • Printable Resources
      • Supported Brands
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Find a Provider
      • Locate a Healthcare Professional
      • MMJ Recommendations
  • Blog
    • Blog: Client Stories
    • Blog: Education
  • About
    • Who We Are
    • In the News
    • Supported Brands
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
  • Donate
  • Register
  • Login
  • Research
    • Observational Research Registry
    • Company Interest
    • Research Library
    • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Observational Research Registry
      • Printable Resources
      • Supported Brands
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Find a Provider
      • Locate a Healthcare Professional
      • MMJ Recommendations
  • Blog
    • Blog: Client Stories
    • Blog: Education
  • About
    • Who We Are
    • In the News
    • Supported Brands
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
Menu
  • Research
    • Observational Research Registry
    • Company Interest
    • Research Library
    • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Observational Research Registry
      • Printable Resources
      • Supported Brands
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Find a Provider
      • Locate a Healthcare Professional
      • MMJ Recommendations
  • Blog
    • Blog: Client Stories
    • Blog: Education
  • About
    • Who We Are
    • In the News
    • Supported Brands
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
  • Donate
  • Register
  • Login

Research Library

A-Z Conditions  Participate in ORR

The Development of Cannabidiol as a Psychiatric Therapeutic: A Review of Its Antipsychotic Efficacy and Possible Underlying Pharmacodynamic Mechanisms

  • Journal : International Neuropsychiatric Disease Journal
  • Publication Year : 2013
  • Authors : Shahin A.M. Jalali; William E. Johnson

Cannabidiol (CBD), a once-considered inert cannabis constituent, is one of two primary
constituents of cannabis, alongside delta-9-tetrahydrocannabinol (∆9-THC/THC). In the
last 30 years, CBD has become implicated with a range of pharmaceutical mechanisms
of great therapeutic interest and utility. This review details the literature speculating
CBD’s attenuation of psychotic symptoms, particularly in light of a marked elevation in
mean THC concentrations, and a concomitant decline in CBD concentrations in the
prevalent U.K street market cannabis derivatives since c. 2000. CBD is purported to
exhibit pharmacology akin to established atypical antipsychotics, whilst THC has been
implicated with the precipitation of psychosis, and the induction of associated symptoms. The aim of the review was to clarify the conjecture surrounding CBD’s antipsychotic
efficacy, before going on to detail prominent theories about its associated
pharmacodynamics. Were CBD’s antipsychotic efficacy established, then there is
potential for major latent anthropological repercussions to manifest, such as significant
elevations in psychosis manifestations in the U.K. The review found a largely affirmative
body of evidence asserting CBD’s antipsychotic efficacy. CBD exhibited capacity to
attenuate natural and artificially induced psychoses in both animal and human cohorts the latter of which included individuals considered resistant to conventional treatment.
CBD also shows promising potential for use as an antipsychotic drug for Parkinson’s
disease (PD) patients with psychosis, owing to its low rate of extra-pyramidal side-effect
induction. A range of potential pharmacological mechanisms behind CBD’s neuroleptic
pharmacology are outlined, with particular emphasis on its prevention of the hydrolysis
and reuptake of the endogenous cannabinoid, anandamide. However, given the nebular
aetiological basis for psychoses, explicit conclusions on how CBD attenuates psychotic
symptoms remains to be determined.

Read the Full Article

Share This:

Share on Twitter Share on Facebook Share on LinkedIn Share on Email
NextCannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptorsNext

Conditions:

  • Mental Illness

Research Information:

Research Keywords:

  • Anandamide, Antipsychotic, cannabidiol, Cannabinoid, CBD, Psychosis, schizophrenia, THC

Search the Research Library >

Follow Us:

Facebook Twitter Youtube

REGISTER WITH THE RoC TODAY!

Realm of Caring focuses on research, education, building community, and improving quality of life. We are an educational resource for consumers, physicians, scientists, governments and the media.
Register now
  • 5040 Corporate Plaza Drive, Suite 7R, Colorado Springs, CO 80919
  • 719-347-5400
  • info@realmofcaring.org

Copyright © 2023 / Realm of Caring Foundation, Inc

  • Privacy
  • Disclaimer